Investors & Newsroom:

Investor FAQ

When was the company founded?
uniQure was founded in 1998 and was initially operated through our predecessor company, Amsterdam Molecular Therapeutics Holding N.V.

Where is the company incorporated?
We are incorporated under the laws of the Netherlands.

When did uniQure go public?
Our common stock began trading on February 5, 2014.
The initial public offering price was US $17.00

When is uniQure’s fiscal year-end?
Our fiscal year ends on December 31 of each year. Our fiscal quarters end on March 31, June 30, September 30 and December 31 of each year.

How is uniQure stock traded?
Our common stock is listed on the NASDAQ Global Market under the symbol QURE.

Who are uniQure's independent auditors?
PricewaterhouseCoopers Accountants N.V.
Westgate
Thomas R. Malthusstraat 5
1066 JR Amsterdam
The Netherlands
31.8879.20072

Who is uniQure's legal counsel?
Matthijs van Blokland
Tafelbergweg 51
1105 BD in Amsterdam
m.vanblokland@uniQure.com
+31 20 240 6172

Where can I get the latest corporate news releases and financial reports?
uniQure’s press release archives can be viewed at: www.uniqure.com/investors-newsroom/press-releases.php
Our financial reports are available at: www.uniqure.com/investors-newsroom/sec-filings.php

How can I view documents uniQure has filed with the Securities & Exchange Commission (SEC)?
uniQure’s SEC filings can be viewed at www.uniqure.com/investors-newsroom/sec-filings.php or www.sec.gov.